Navigation Links
Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients

CHICAGO, and ANN ARBOR, Mich., June 3, 2011 /PRNewswire/ -- Everist Genomics today announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago.


OncoDefender-CRC examines expression levels of a panel of genes extracted from formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and uses a proprietary computer-generated decision rule to stratify patients into 'high-risk' and 'low-risk' categories for assessing likelihood of recurrence.  

Accurately identifying Stage I/II colorectal cancer patients who are at risk of recurrence represents a significant unmet medical need as mortality rates for early stage disease are higher than generally realized. "About one in seven patients with Stage I and one in three patients with Stage II colorectal cancer will ultimately experience a recurrence," said Peter F. Lenehan, M.D., Ph.D. Chief Medical Officer of Everist Genomics. "In this sub-population of patients who recur, the associated mortality rates are 50 percent and 80 percent, respectively."

The study confirmed that OncoDefender-CRC was able to differentiate those patients at high risk from those at low risk for cancer recurrence within 3 years after potentially curative surgery more accurately than assessments based on National Comprehensive Cancer Network (NCCN) Guidelines, widely accepted as providing "best practices" in oncology.  The study included patient samples from four international sites.

For stages I/II colorectal cancer (n=115), OncoDefender-CRC correctly classified 32/46 cases of recurrence and 38/69 cases of non-recurrence (sensitivity 70%, specificity 55%). 'High-risk' patients had a significantly higher probability of recurrence within 36 months than 'low-risk' patients (PPV 0.51, NPV 0.73, HR 2.06 (95% CI: 1.10 to 3.86; p=0.020)). In contrast, the standard prognostic guidelines described by the NCCN Guidelines were unable to differentiate recurrence risk in this population (p=0.315).

Notably, the study found that Stage I colorectal cancer patients that were deemed 'high-risk' by the test recurred at a rate more than triple that for patients deemed 'low-risk'. "The updated data demonstrate that OncoDefender-CRC provides a more targeted stratification of patients, independent of other recognized prognostic variables, such as age, T-stage, grade, tumor location and lymphovascular invasion," said Lenehan.

Recent research in cancer genomics has shown that Stage I/II colorectal cancer tumors can differ greatly from other tumors that are classified in the same stage, indicating that some tumors present observable high-risk characteristics. Tumors that present such high-risk characteristics can be more than 20 times more likely to lead to a recurrence than tumors with low-risk characteristics. By more accurately identifying patients who have high-risk tumors, Lenehan said healthcare providers can more effectively target their treatment decisions, thereby potentially improving clinical outcomes.

"Recent literature shows that patients identified with high-risk early stage tumors benefit significantly from surgical removal of the tumor followed by adjuvant therapy," Lenehan said. "Until recently, however, physicians have not been equipped with prognostic tests that can accurately distinguish high-risk early stage tumors from low-risk tumors."

"The data from the OncoDefender-CRC study validate the effectiveness of this node-negative prognostic test in determining recurrence risk for this population, demonstrating the potential for optimizing post-op clinical management and patient stratification in therapeutic clinical trials," he concluded.

About OncoDefender-CRC

The OncoDefender-CRC assay, which is the only molecular prognostic test capable of accurately predicting risk of recurrence of cancer in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor, is commercially available in the United States.  The final 5-gene prognostic test was generated through genetic programming analysis of 422 CRC- and stroma-related genes. The test is performed at Everist Genomics' Ann Arbor-based clinical laboratory, which has been certified through the most stringent requirements (High Complexity) of the United States Clinical Laboratory Improvement Acts.  

As part of the company's commitment to make the test available to all patients regardless of insurance coverage or financial status, Everist Genomics offers a generous financial assistance program that can cover up to 80 percent of the cost of the OncoDefender-CRC test.

The test is performed on formalin-fixed paraffin-embedded cancer tissue taken at the time of surgery, and test results are issued within 7 to 10 days of receipt of tissues. The test does not report indeterminate or "no-call" results from any samples that meet quality acceptance and processing criteria.

About Colorectal Cancer

Colorectal cancer is one of the major causes of cancer death worldwide, accounting for more than 150,000 new cases and 55,000 deaths in the United States every year and 125,000 deaths each year in Europe.(1)  To date, surgery, followed by adjuvant chemotherapy when appropriate, is the mainstay of therapy for patients with localized disease. Of the estimated 68,000 patients that will be diagnosed with early stage colorectal cancer this year in the US, approximately 15% of stage I patients and 30% of stage II patients will recur following curative surgery. Many of these latter patients may have been cured or had their lives prolonged had they been more accurately identified as being at 'high-risk' for tumor recurrence and received post-surgical resection adjuvant therapy.  Identifying those patients at high-risk for colorectal cancer recurrence can reduce mortality, morbidity and cost of care.  

About Everist Genomics

Everist Genomics is a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence and proprietary point-of-care equipment for the evaluation and management of cardiovascular disease. Using its patented Evolver™ technology platform, Everist Genomics is successfully developing and commercializing entirely new classes of patent-protected molecular biomarkers and sensor technologies which employ proprietary equipment, devices and software to help physicians make individualized treatment and drug prescribing decisions.  The privately owned company was founded in 2002 and is located in Ann Arbor, Michigan.  For more information, please visit

(1) Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. Cancer J Clin 57:168–185, 2007.  

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
2. Genetics Squared Changes Name To Everist Genomics
3. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Rosetta Genomics Announces Issuance of Additional U.S. Patent
6. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
7. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
8. NeoGenomics Schedules its Q3 2010 Earnings Release for October 28, 2010
9. BioInformatics, LLC New Market Reports - RNAi, Genomics and Membrane Protein Structure
10. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
11. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: AGN ) ... New York State Attorney General,s Office ... Act, and other statutes with the Attorney General over the ... cease marketing and selling the now generic version of memantine ... no liability, has released its counterclaims against New ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... - Will Also Offer Point -of- ... --> - Will Also Offer Point ... --> - Will Also Offer ... (CME) Elsevier , a world-leading provider of ... diagnostic imaging textbooks and decision support tools, as well as prominent ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number ... first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired ... Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the common symptoms ... hands, and dry skin. But many people who find their cholesterol levels and weight ... of their thyroid, especially if they don’t have any of the other symptoms. , ...
(Date:11/25/2015)... ... 2015 , ... Students and parents have something to be thankful for this ... Impact awards. California Casualty is proud to support the contest designed to ... reckless driving, the number one killer of young drivers. , Almost 1,000 entries ...
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
Breaking Medicine News(10 mins):